Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?

Table 4

Impact of the AR/ER, AR/PgR, and ER/PgR ratios, assessed on primary tumors, on OS in the overall series (no. 159).

Median ratios (range)
AR/ER	0.95 (0 - 95)
AR/PgR	1.59 (0 - 100)
ER/PgR	1.35 (0 - 100)
OS according to best cut-off ratio
Median follow-up: 78 months (range 3-155)
	no. deaths/no. patients	Median OS (months); (95% CI)	HR (95% CI)	p
Overall	63/104	62 (50-71)	-	-
AR/ER
<1.30	53/88	63 (50 - 76)	1.00
≥1.30	10/16	52 (23 - NR)	1.10 (0.56 - 2.16)	0.792
AR/PgR
<1.70	31/51	66 (53 - 84)	1.00
≥1.70	32/53	46 (36 - 65)	1.45 (0.88 - 2.39)	0.147
ER/PgR
<2.00	27/49	81 (62 - 88)	1.00
≥2.00	36/55	46 (36 - 60)	1.90 (1.14 - 3.17)	0.014

AR, androgen receptor; ER, estrogen receptor; PgR, progesterone receptor; OS, overall survival: HR, hazard ratio; CI, confidence interval; ND, not determinable; NR, not reached.